HIGHLIGHTS
- who: Valentina Rocca et al. from the Department of Clinical and Experimental Medicine, Magna Græcia University of Catanzaro, Department of Health Sciences, Magna Græcia University of Catanzaro, Catanzaro, Italy have published the paper: Li-Fraumeni Syndrome: Mutation of TP53 Is a Biomarker of Hereditary Predisposition to Tumor: New Insights and Advances in the Treatment, in the Journal: Cancers 2022, 14, 3664. of 15/06/2022
- what: The diagnosis is usually confirmed by genetic testing for the identification of mutations; therefore these mutations are considered the biomarkers associated with the tumor spectrum of Here . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.